Literature DB >> 30058141

Editorial: Lymphocyte Highs and Lows With Baricitinib.

Deepak A Rao1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30058141      PMCID： PMC6261677          DOI： 10.1002/art.40681

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   10.995


× No keyword cloud information.
  13 in total

Review 1.  Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs.

Authors:  Jason G Cyster
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

2.  Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism.

Authors:  Qing Chen; Daniel T Fisher; Kristen A Clancy; Jean-Marc M Gauguet; Wan-Chao Wang; Emily Unger; Stefan Rose-John; Ulrich H von Andrian; Heinz Baumann; Sharon S Evans
Journal:  Nat Immunol       Date:  2006-12       Impact factor: 25.606

Review 3.  The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.

Authors:  Jennifer A Hodge; Thomas T Kawabata; Sriram Krishnaswami; James D Clark; Jean-Baptiste Telliez; Martin E Dowty; Sujatha Menon; Manisha Lamba; Samuel Zwillich
Journal:  Clin Exp Rheumatol       Date:  2016-03-10       Impact factor: 4.473

4.  Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.

Authors:  B Strober; M Buonanno; J D Clark; T Kawabata; H Tan; R Wolk; H Valdez; R G Langley; J Harness; A Menter; K Papp
Journal:  Br J Dermatol       Date:  2013-11       Impact factor: 9.302

5.  Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis.

Authors:  Maxime Samson; Sylvain Audia; Nona Janikashvili; Marion Ciudad; Malika Trad; Jennifer Fraszczak; Paul Ornetti; Jean-Francis Maillefert; Pierre Miossec; Bernard Bonnotte
Journal:  Arthritis Rheum       Date:  2012-08

6.  Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.

Authors:  Hendrik Schulze-Koops; Vibeke Strand; Chudy Nduaka; Ryan DeMasi; Gene Wallenstein; Kenneth Kwok; Lisy Wang
Journal:  Rheumatology (Oxford)       Date:  2016-10-22       Impact factor: 7.580

7.  The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.

Authors:  D L Boyle; K Soma; J Hodge; A Kavanaugh; D Mandel; P Mease; R Shurmur; A K Singhal; N Wei; S Rosengren; I Kaplan; S Krishnaswami; Z Luo; J Bradley; G S Firestein
Journal:  Ann Rheum Dis       Date:  2014-11-14       Impact factor: 19.103

8.  Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.

Authors:  Yoshiya Tanaka; Iain B McInnes; Peter C Taylor; Nicole L Byers; Lei Chen; Stephanie de Bono; Maher Issa; William L Macias; Veronica Rogai; Terence P Rooney; Douglas E Schlichting; Steven H Zuckerman; Paul Emery
Journal:  Arthritis Rheumatol       Date:  2018-10-22       Impact factor: 10.995

Review 9.  Leveraging blood and tissue CD4+ T cell heterogeneity at the single cell level to identify mechanisms of disease in rheumatoid arthritis.

Authors:  Chamith Y Fonseka; Deepak A Rao; Soumya Raychaudhuri
Journal:  Curr Opin Immunol       Date:  2017-09-06       Impact factor: 7.486

10.  Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissue

Authors:  Laura T Donlin; Deepak A Rao; Kevin Wei; Kamil Slowikowski; Mandy J McGeachy; Jason D Turner; Nida Meednu; Fumitaka Mizoguchi; Maria Gutierrez-Arcelus; David J Lieb; Joshua Keegan; Kaylin Muskat; Joshua Hillman; Cristina Rozo; Edd Ricker; Thomas M Eisenhaure; Shuqiang Li; Edward P Browne; Adam Chicoine; Danielle Sutherby; Akiko Noma; Chad Nusbaum; Stephen Kelly; Alessandra B Pernis; Lionel B Ivashkiv; Susan M Goodman; William H Robinson; Paul J Utz; James A Lederer; Ellen M Gravallese; Brendan F Boyce; Nir Hacohen; Costantino Pitzalis; Peter K Gregersen; Gary S Firestein; Soumya Raychaudhuri; Larry W Moreland; V Michael Holers; Vivian P Bykerk; Andrew Filer; David L Boyle; Michael B Brenner; Jennifer H Anolik
Journal:  Arthritis Res Ther       Date:  2018-07-11       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.